VYGR - Two Catalysts For Axovant Sciences In March
Axovant Sciences Ltd (AXON) is approaching two key catalysts which may attract the attention of the markets. When I last wrote about the company, I noted that I didn't like the decisions being made at AXON. Throughout 2019 we may begin to see if the company's risky decision, to pivot into a gene therapy company, has paid off. The first chance to see some data from the company's new gene therapy programs is coming in March.
Figure 1: The AXON pipeline now consists entirely of gene therapies with the company having cast